Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 14/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600987 | 0.84 | RIPK2 (0.46) | PDE4BRIPK2MAPK14GAK | |
| SCHEMBL17059449 | 0.76 | RIPK2 (0.50) | PDE4BRIPK2KDRRETMAPK14 | |
| SCHEMBL30880575 | 0.73 | RIPK2 (0.50) | PDE4BRIPK2KDRRETMAPK14 | |
| SCHEMBL856757 | 0.73 | PDE4B (0.46) | PDE4BRIPK2KDRRETMAPK14 | |
| SCHEMBL600488 | 0.73 | RIPK2 (0.50) | PDE4BRIPK2KDRRETMAPK14 | |
| SCHEMBL359724 | 0.72 | CYP1A2 (0.43) | — | |
| SCHEMBL13652287 | 0.72 | LMNA (0.43) | — | |
| SCHEMBL23269707 | 0.71 | TP53 (0.50) | PDE4B | |
| SCHEMBL10106290 | 0.70 | GAK (0.46) | PDE4BRIPK2KDRRETMAPK14 | |
| SCHEMBL24027143 | 0.69 | PIK3CA (0.42) | RIPK2KDRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | PDE4B 601/4885RIPK2 480/4885KDR 523/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | PDE4B 601/4885RIPK2 480/4885KDR 523/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | PDE4B 601/4885RIPK2 480/4885KDR 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.